Welcome to our dedicated page for Oculis Holding SEC filings (Ticker: OCSAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Oculis Holding's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Oculis Holding's regulatory disclosures and financial reporting.
Oculis Holding AG filing reports a proposed sale of 25,000 common shares through UBS Financial Services on 09/23/2025, with an aggregate market value of $442,500 based on the notice. The filing shows 43,662,402 shares outstanding. The shares were acquired on 03/02/2023 as issuance of earnout shares from the issuer and fully paid on that date. The filer reports no sales of the issuer's securities in the past three months and includes the standard representation that the seller is unaware of any undisclosed material adverse information.
FAQ
What is the current stock price of Oculis Holding (OCSAW)?
